23-Valent Pneumococcal Polysaccharide Vaccine Uptake in the United States Air Force HIV Program

Thad F. Ocampo, Tuan Le, Peter E. Matthews, Jason F. Okulicz

Research output: Contribution to journalArticle


Streptococcus pneumoniae infection is a predominant cause of bacterial infection in HIV-infected individuals. However, reported rates of pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) are variable. We evaluated uptake of PPV23 in patients diagnosed with HIV between 1996 and 2012 (n = 507) in the United States Air Force, a centralized HIV program with free access to care including vaccines and medications. A total of 411 (81.1%) patients received at least 1 PPV23 dose. The PPV23 vaccination within 1 year of diagnosis was greater for those diagnosed between 2004 and 2012 (n = 184, 86%) compared with 1996 to 2003 (n = 104, 56.5%; P <.001). For those with ≥6 years of follow-up, receipt of a second recommended PPV23 dose was greater for those diagnosed between 1996 and 2003 (n = 52, 57.8%) compared with 2004 to 2012 (n = 9, 28.1%; P =.004). Although first PPV23 vaccination was high in recent years, process improvement efforts are underway to overcome barriers and improve uptake of pneumococcal vaccines in our program.

Original languageEnglish (US)
Pages (from-to)286-290
Number of pages5
JournalJournal of the International Association of Providers of AIDS Care
Issue number4
Publication statusPublished - Jul 1 2016
Externally publishedYes



  • HIV
  • pneumococcal polysaccharide vaccine
  • Streptococcus pneumoniae infection

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases

Cite this